A chance to see the disease coming, decades before it steals anything.
Décadas antes de um nome ser esquecido, proteínas já começam seu trabalho silencioso no cérebro. O neurocientista brasileiro Wagner Brum apresenta um exame de sangue capaz de detectar essas marcas moleculares do Alzheimer com até trinta anos de antecedência — não como cura, mas como janela. Em um país onde o acesso ao diagnóstico avançado sempre foi desigual, essa possibilidade carrega o peso de uma promessa antiga: conhecer o que vem antes que ele chegue.
- O Alzheimer avança em silêncio por décadas, e a maioria dos diagnósticos chega tarde demais para qualquer intervenção significativa.
- O exame Petal 217 detecta alterações nas proteínas amiloide e tau muito antes dos primeiros sintomas cognitivos, abrindo uma janela diagnóstica sem precedentes.
- Apesar do potencial, o teste ainda não é recomendado como triagem para pessoas sem sintomas — seu uso mais seguro é como auxílio diagnóstico para quem já apresenta queixas de memória.
- Menos de 1% dos casos de Alzheimer têm origem hereditária, o que transforma a forma como pacientes e famílias devem interpretar seu próprio risco.
- O estudo IB Bioneuro busca validar o exame na população brasileira e criar infraestrutura para aplicá-lo em larga escala, da atenção primária às clínicas especializadas.
Wagner Brum fala com a calma de quem persegue um problema há anos. O neurocientista brasileiro acaba de ser reconhecido por seu trabalho em detecção do Alzheimer e quer explicar o que pode mudar na forma como a doença é identificada: um exame de sangue capaz de encontrar suas impressões digitais décadas antes de qualquer sintoma aparecer.
O Alzheimer funciona como uma acumulação lenta. Duas proteínas — amiloide e tau — começam a se aglomerar no cérebro entre vinte e trinta anos antes dos primeiros sinais cognitivos. A pessoa se sente bem. Não sabe o que acontece dentro do próprio crânio. O exame chamado Petal 217 pode detectar essas alterações muito antes que qualquer médico as perceba no comportamento do paciente. Brum é preciso sobre os limites: por ora, o teste funciona melhor como ferramenta diagnóstica para quem já tem queixas, ajudando a distinguir o Alzheimer de outras condições que imitam seus sinais iniciais.
Há algo mais que Brum quer que as pessoas entendam: a forma hereditária da doença, aquela que percorre famílias, representa menos de 1% dos casos. A maioria do Alzheimer é esporádica — chega sem aviso, sem histórico familiar que o anuncie. Essa distinção muda profundamente como cada pessoa deve interpretar seu próprio risco.
Brum coordena o IB Bioneuro, iniciativa brasileira sobre biomarcadores em doenças neurodegenerativas, ao lado do neurocientista Eduardo Zimmer, com apoio do Ministério da Saúde. O objetivo central é validar se o exame funciona tão bem na população brasileira quanto em outros contextos — e depois escalar.
O verdadeiro desafio não é científico, mas prático. Exames de PET e punções lombares nunca se difundiram no Brasil por serem caros ou invasivos. Um exame de sangue muda essa equação — simples, barato, aplicável em uma unidade básica de saúde. Mas isso exige que médicos saibam como solicitá-lo, interpretá-lo e agir a partir dele. Não apenas neurologistas, mas os clínicos gerais que atendem pacientes com queixas de memória todos os dias. A janela que Brum descreve não é uma cura. É, por ora, a chance de saber — antes que a doença leve qualquer coisa consigo.
Wagner Brum sits across from the camera with the measured confidence of someone who has spent years chasing a problem that kills slowly and quietly. The Brazilian neuroscientist has just won recognition for his work on Alzheimer's detection, and he wants to talk about something that could change how the disease is caught: a blood test that can spot the disease's fingerprints decades before a person forgets their own name.
Alzheimer's works like a slow accumulation. Two proteins—amyloid and tau—begin to clump together in the brain, forming plaques that gradually strangle neural function. The disease doesn't announce itself. It whispers for years before it speaks. Brum explains that these proteins typically begin their destructive work somewhere between twenty and thirty years before the first cognitive symptoms appear. For most of that time, the person feels fine. They have no idea what's happening inside their skull.
The blood test is called Petal 217, and it can detect these protein changes long before any doctor would notice them in a patient's behavior or memory. This is the revolution Brum is describing—not a cure, but a window. A chance to see the disease coming. The test is beginning to move into clinical practice now, though carefully. Brum is clear about the limits: for people without symptoms, the test is not yet recommended as a screening tool. It works best as a diagnostic aid for people who are already experiencing cognitive problems, helping doctors distinguish Alzheimer's from other conditions that mimic its early signs.
But there is something else Brum wants people to understand about Alzheimer's, something that shapes how we think about risk and inheritance. The disease has a genetic component—that much is true. But the hereditary form, the kind that runs through families like a curse, accounts for less than one percent of all cases. Most Alzheimer's is sporadic, meaning it arrives without warning, without a family history to announce it. A person's parents may have had the disease without passing down the genetic vulnerability. This distinction matters because it changes how people interpret their own risk, how they understand what they inherited and what they didn't.
Brum coordinates a major research initiative called IB Bioneuro—the Brazilian Initiative for Biomarkers in Neurodegenerative Diseases—working alongside neuroscientist Eduardo Zimmer. The study has backing from Brazil's Ministry of Health and aims to answer a crucial question: does this blood test work as well in Brazilian populations as it has elsewhere? The Zimmer Lab, where Brum conducts his research, has been built through competitive grants and support from CAPES, the Serrapilheira Institute, and IDOR Pioneer Science. Brum is the fourth scientist from the group to receive major recognition for this work.
The real challenge ahead is not scientific but practical. Previous methods for diagnosing Alzheimer's—PET scans, spinal taps—never took root widely in Brazil because they were expensive or invasive or both. A blood test changes the equation. It is simple. It is cheap. It could work in a primary care clinic as easily as in a specialist's office. But only if doctors know how to order it, how to interpret it, what to do with the results. Brum is clear about what needs to happen next: validate the test in the Brazilian population, scale it up, and train the healthcare workers who will actually use it—not just the neurologists, but the general practitioners who see patients with memory complaints every day.
The window Brum is describing is not a cure. It is not even a treatment, not yet. But it is something that has been missing: the chance to know. To see the disease before it steals anything. In a country where access to advanced diagnostics has always been unequal, a simple blood test could mean the difference between early intervention and late diagnosis, between hope and resignation.
Notable Quotes
The proteins begin accumulating in the brain around 20 to 30 years, on average, before symptoms start.— Wagner Brum
Our main challenge is showing the test works in the Brazilian population and implementing it at scale, while training healthcare professionals to interpret and order it.— Wagner Brum
The Hearth Conversation Another angle on the story
When you say the proteins start accumulating twenty to thirty years before symptoms, what does that mean for someone getting this test today?
It means you could have a positive result and feel completely normal for decades. You're not sick yet. The test is showing a process that's underway, not a disease that's active.
So why test at all if someone has no symptoms?
That's exactly the question we're wrestling with. Right now, we're not recommending it for screening healthy people. But if someone comes in complaining about memory problems, the test helps us know whether it's Alzheimer's or something else—depression, thyroid issues, normal aging.
You mentioned most Alzheimer's isn't hereditary. Why does that matter so much to you?
Because people carry so much fear about inheritance. They think if their parent had it, they're doomed. But ninety-nine percent of cases are sporadic. You can't inherit what wasn't passed down. That distinction gives people permission to stop catastrophizing.
What's the biggest obstacle to making this test available across Brazil?
Not the science. The science works. It's training. A doctor in a small city needs to know when to order this test and what the result means. That's the real work ahead—not discovery, but implementation.
And if you succeed?
Then a person with early memory loss gets an answer instead of uncertainty. They get time to plan, to seek treatment early, to understand what's happening. That's not nothing.